Imviva’s CTA313 Lupus Drug Shows Promising Remission Results

Imviva’s CTA313 Lupus Drug Shows Promising Remission Results

By Daniella Parra Imviva Biotech said data showed its CTA313 drug resulted in 50% of patients going into remission for systemic lupus. Many patients experience incomplete responses, recurrent flares and long-term treatment-related toxicity, it said. “The clinical activity observed with...

Input your search keywords and press Enter.